Developmentally regulated antigens for immunologic targeting of pediatric brain tumors
用于儿童脑肿瘤免疫靶向的发育调节抗原
基本信息
- 批准号:10751884
- 负责人:
- 金额:$ 41.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2025-07-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive Cell TransfersAntigensBrainBrain NeoplasmsBrain StemBrain Stem GliomaBypassCancer EtiologyCerebellumChildChildhoodChildhood Brain NeoplasmChildhood Central Nervous System NeoplasmChildhood Malignant Brain TumorClinical ResearchDataDendritic CellsDevelopmentDevelopmental ProcessDiseaseDoctor of PhilosophyExcisionGenomicsGliomaGrowthHumanImmune TargetingImmunologicsImmunotherapyIn VitroInstitutionLeadLinkMalignant NeoplasmsMalignant neoplasm of brainMethodsMolecularOncologyOutcomePhysiologic pulsePre-Clinical ModelPrimary NeoplasmPublicationsRNARecurrenceSHH geneSolid NeoplasmSourceSpecificityT-LymphocyteTherapeuticTissuesTranscendbrain tissuechildhood cancer mortalitycross reactivityefficacy evaluationgene productgenomic profilesimmunogenicin vivomedulloblastomamedulloblastoma cell linemouse modelneoplastic cellneuralnovelphase 2 studypostnatalpreclinical studyresponsesafety and feasibilitytumor
项目摘要
PROJECT SUMMARY/ABSTRACT:
Brain tumors are the number one cause of cancer related deaths in children. Medulloblastoma (MB) is
the most common malignant pediatric brain tumor, while brainstem gliomas (BSG) are the most lethal. Though
numerous preclinical and clinical studies have demonstrated potential therapeutic benefits for immunotherapy in
solid tumors, malignant brain tumors remain universally lethal. In response, our group has pioneered an adoptive
cellular therapy platform that relies on the transfer of tumor-reactive T cells and our publications demonstrate
that this platform is efficacious against orthotopic high grade gliomas (KR158B, GL261), Group 3 MB (NSC),
Sonic hedgehog MB (Ptc), and brainstem glioma (K2). In this proposal, our objective is to increase the specificity
and efficacy of adoptive cellular therapy by employing a more targeted approach against embryonal tumors,
specifically MB and brainstem gliomas (BSG).
Recent elegant studies have identified links between ontogeny and oncology, describing that
dysregulation in neural developmental processes lead to childhood CNS tumors, suggesting these cancers arise
as a consequence of abnormal developmental processes. This provides great opportunity to leverage developing
neural tissue as a source of antigens against MB and BSG. We refer to this genomic intersection between
developing tissue and tumors as developmental antigens (DevAg). In this proposal we will identify the DevAgs
in both MB and BSG and leverage them for immunological targeting of these tumors. Targeting these
developmentally regulated antigens not only negates the requirement for primary tumor resection but also limits
potential cross-reactivity with normal gene products. Importantly, this indicates that developing cerebellum do
share immunogenic antigens with different subtypes of MB and that multiple subtypes of MB can be targeted by
developmental antigens. To our knowledge, our studies are the first to 1. Utilize developing brain antigens to
target syngeneic MB and BSG murine models and 2. demonstrate antitumor efficacy using a novel method of
targeted enrichment to select for specific antigens. This approach has profound implications in safely and
effectively targeting MB and BSG.
项目总结/摘要:
脑肿瘤是儿童癌症相关死亡的头号原因。髓母细胞瘤(MB)是
最常见的恶性小儿脑肿瘤,而脑干神经胶质瘤(BSG)是最致命的。虽然
许多临床前和临床研究已经证明了免疫疗法在以下疾病中的潜在治疗益处:
实体瘤、恶性脑肿瘤仍然普遍致命。作为回应,我们的团队开创了一种
依赖于肿瘤反应性T细胞转移的细胞治疗平台,我们的出版物表明,
该平台对原位高级别神经胶质瘤(KR 158 B,GL 261),第3组MB(NSC),
Sonic hedgehog MB(Ptc)和脑干胶质瘤(K2)。在本提案中,我们的目标是增加特异性
和通过采用针对胚胎肿瘤的更有针对性的方法的过继细胞治疗的功效,
特别是MB和脑干神经胶质瘤(BSG)。
最近的研究已经确定了个体发育和肿瘤学之间的联系,描述了
神经发育过程中的失调导致儿童中枢神经系统肿瘤,这表明这些癌症的发生
是异常发育过程的结果这为利用发展中国家的
神经组织作为抗MB和BSG的抗原来源。我们把这种基因组交叉点
发育组织和肿瘤作为发育抗原(DevAg)。在本提案中,我们将确定DevAgs
在MB和BSG两者中,并利用它们用于这些肿瘤的免疫靶向。靶向这些
发育调节的抗原不仅否定了原发性肿瘤切除的要求,
与正常基因产物的潜在交叉反应性。重要的是,这表明发育中的小脑
与MB的不同亚型共享免疫原性抗原,并且MB的多个亚型可以通过
发育抗原据我们所知,我们的研究是第一个。利用发育中的脑抗原
靶向同基因MB和BSG鼠模型和2.使用一种新的方法证明抗肿瘤功效,
靶向富集以选择特异性抗原。这种方法在安全和
有效地针对MB和BSG。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Catherine T Flores其他文献
Catherine T Flores的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Catherine T Flores', 18)}}的其他基金
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
造血干细胞克服了针对脑肿瘤的 PD-1 阻断疗法的耐药性
- 批准号:
10478097 - 财政年份:2020
- 资助金额:
$ 41.94万 - 项目类别:
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
造血干细胞克服了针对脑肿瘤的 PD-1 阻断疗法的耐药性
- 批准号:
9885762 - 财政年份:2020
- 资助金额:
$ 41.94万 - 项目类别:
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
造血干细胞克服了针对脑肿瘤的 PD-1 阻断疗法的耐药性
- 批准号:
10260393 - 财政年份:2020
- 资助金额:
$ 41.94万 - 项目类别:
Hematopoietic stem cells overcome treatment resistance to PD-1 blockade against brain tumors
造血干细胞克服了针对脑肿瘤的 PD-1 阻断疗法的耐药性
- 批准号:
10677644 - 财政年份:2020
- 资助金额:
$ 41.94万 - 项目类别:
Hematopoietic stem cells overcome treatment resistance to adoptive cellular therapy against malignant gliomas
造血干细胞克服了恶性胶质瘤过继性细胞疗法的治疗耐药性
- 批准号:
10241491 - 财政年份:2019
- 资助金额:
$ 41.94万 - 项目类别:
Hematopoietic stem cells overcome treatment resistance to adoptive cellular therapy against malignant gliomas
造血干细胞克服了恶性胶质瘤过继性细胞疗法的治疗耐药性
- 批准号:
10652577 - 财政年份:2019
- 资助金额:
$ 41.94万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Identification of targeted membrane antigens of human brain microvascular endothelial cells in relapsing-remitting multiple sclerosis
复发缓解型多发性硬化症人脑微血管内皮细胞靶向膜抗原的鉴定
- 批准号:
19K07975 - 财政年份:2019
- 资助金额:
$ 41.94万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
RNA-Based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
基于 RNA 的免疫疗法靶向脑肿瘤干细胞特有的抗原
- 批准号:
7822434 - 财政年份:2008
- 资助金额:
$ 41.94万 - 项目类别:
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
基于 RNA 的免疫疗法靶向脑肿瘤干细胞特有的抗原
- 批准号:
8106189 - 财政年份:2008
- 资助金额:
$ 41.94万 - 项目类别:
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
基于 RNA 的免疫疗法靶向脑肿瘤干细胞特有的抗原
- 批准号:
7665453 - 财政年份:2008
- 资助金额:
$ 41.94万 - 项目类别:
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
基于 RNA 的免疫疗法靶向脑肿瘤干细胞特有的抗原
- 批准号:
8270511 - 财政年份:2008
- 资助金额:
$ 41.94万 - 项目类别: